1. Home
  2. VIGL vs YSXT Comparison

VIGL vs YSXT Comparison

Compare VIGL & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • YSXT
  • Stock Information
  • Founded
  • VIGL 2020
  • YSXT 2011
  • Country
  • VIGL United States
  • YSXT China
  • Employees
  • VIGL N/A
  • YSXT N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • YSXT Automotive Aftermarket
  • Sector
  • VIGL Health Care
  • YSXT Consumer Discretionary
  • Exchange
  • VIGL Nasdaq
  • YSXT Nasdaq
  • Market Cap
  • VIGL 89.3M
  • YSXT 87.9M
  • IPO Year
  • VIGL 2022
  • YSXT 2024
  • Fundamental
  • Price
  • VIGL $3.03
  • YSXT $2.77
  • Analyst Decision
  • VIGL Strong Buy
  • YSXT
  • Analyst Count
  • VIGL 5
  • YSXT 0
  • Target Price
  • VIGL $21.00
  • YSXT N/A
  • AVG Volume (30 Days)
  • VIGL 642.5K
  • YSXT 96.4K
  • Earning Date
  • VIGL 03-25-2025
  • YSXT 01-01-0001
  • Dividend Yield
  • VIGL N/A
  • YSXT N/A
  • EPS Growth
  • VIGL N/A
  • YSXT N/A
  • EPS
  • VIGL N/A
  • YSXT 0.21
  • Revenue
  • VIGL N/A
  • YSXT $58,546,729.00
  • Revenue This Year
  • VIGL N/A
  • YSXT N/A
  • Revenue Next Year
  • VIGL N/A
  • YSXT N/A
  • P/E Ratio
  • VIGL N/A
  • YSXT $13.35
  • Revenue Growth
  • VIGL N/A
  • YSXT 18.92
  • 52 Week Low
  • VIGL $1.49
  • YSXT $2.06
  • 52 Week High
  • VIGL $6.06
  • YSXT $6.27
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 77.87
  • YSXT N/A
  • Support Level
  • VIGL $2.71
  • YSXT N/A
  • Resistance Level
  • VIGL $2.95
  • YSXT N/A
  • Average True Range (ATR)
  • VIGL 0.21
  • YSXT 0.00
  • MACD
  • VIGL 0.03
  • YSXT 0.00
  • Stochastic Oscillator
  • VIGL 86.18
  • YSXT 0.00

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares

YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.

Share on Social Networks: